SCHEMBL2118706

SCHEMBL2118706

COc1ccc(S(=O)(=O)Nc2cc(-c3ccco3)ccc2C)nc1

nearest known ligand 0.45

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
TRIM24 O15164 2/20 0.45
GHSR Q92847 7/20 0.43
ALPL P05186 1/20 0.42
MAPT P10636 2/20 0.41
RAB9A P51151 2/20 0.41
NPC1 O15118 1/20 0.41
LMNA P02545 1/20 0.40
TP53 P04637 1/20 0.40
ALDH1A1 P00352 2/20 0.39
CYP2C9 P11712 1/20 0.39
TSHR P16473 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
KEAP1 Q14145 1/20 0.39
KAT6A Q92794 1/20 0.38
GLO1 Q04760 1/20 0.38
POLB P06746 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2120124 0.87 TRIM24 (0.48) TRIM24GHSRMAPTRAB9ANPC1
SCHEMBL2120142 0.86 TRIM24 (0.46) TRIM24GHSRALPLMAPTRAB9A
SCHEMBL2116789 0.84 GHSR (0.53) GHSRMAPTRAB9ANPC1LMNA
SCHEMBL2118122 0.82 MAPT (0.48) GHSRMAPTRAB9ANPC1ALDH1A1
SCHEMBL2118125 0.81 TRIM24 (0.48) TRIM24MAPTRAB9ANPC1ALDH1A1
SCHEMBL2121581 0.81 TRIM24 (0.49) TRIM24GHSRALPLMAPTALDH1A1
SCHEMBL2119284 0.81 TRIM24 (0.45) TRIM24GHSRALPLMAPTRAB9A
SCHEMBL2118328 0.81 TRIM24 (0.45) TRIM24GHSRALPLMAPTRAB9A
SCHEMBL2116620 0.80 TRIM24 (0.46) TRIM24GHSRALPLMAPTPOLB
SCHEMBL2118182 0.79 TRIM24 (0.54) TRIM24GHSRMAPTRAB9ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120095012-A1 TOLUIDINE SULFONAMIDES AND THEIR USE ELARA PHARMACEUTICALS GMBH (DE) 2012-04-19 US disclosed
EP-2382190-A1 TOLUIDINE SULFONAMIDES AND THEIR USE AS-INHIBITORS European Molecular Biology Laboratory (EMBL) (DE) 2011-11-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120095012-A1 TOLUIDINE SULFONAMIDES AND THEIR USE HIF1A, HIF1AN, EGLN3 TRIM24 2142/4885GHSR 1390/4885ALPL 3436/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.